The FDA said it has identified 76 cases of drug-induced liver injuries with reasonable evidence of being causally linked to ...

By Puyaan Singh March 31 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has identified cases of liver ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.

Biopharma company Amgen plans to add 370 jobs as part of a new, $1.02 billion investment in Holly Springs. It’s the latest move by the company to expand manufacturing capacity in the fast-growing ...

Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.

Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate's inability to meet ...

The EMA's human medicines committee has recommended approval of Amgen's bispecific T-cell engager (BiTE) – Imdylltra – as a second-line treatment option for extensive-stage small cell lung cancer ...

A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to continue marketing a high dose of a pricey cancer treatment instead of a lower dose that is less expensive ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.